Breakthrough Pain Relief with JAN123.

What is JAN123?

JAN 123, is a medication that is used to treat addiction. However, recent evidence suggests that at low doses (5mg or less) it has very unique effects at treating pain and the disease cascade associated with complex regional pain syndrome (CRPS).

How Does It Work?

  • Acts on the Toll-Like Receptor (TLR) to reduce pain.
  • Increases the body’s natural painkillers (endorphins).
  • Decreases the activity of microglial cells, which are responsible for pain.
  • Reduces the activity of interleukins involved in nerve inflammation.
  • Uniquely suited to treat the disease process in CRPS.

What is CRPS?

Complex Regional Pain Syndrome is a rare, orphan disease characterized by severe pain, usually starting in an extremity, and associated with extreme swelling, limited range of motion, changes to the skin or bone structure, and debilitating pain

file_icon

Our novel formulation of JAN123 has received orphan drug status from the FDA.

Read Article

“We look forward to running a large-scale clinical trial and eventually FDA approval to help patients suffering from CRPS.”

Dr. Amol Soin

Read Articles and Clinical Data

Systematic Review Done by Aleya Therapeutics

Published in a major medical journal, this review article written by the Alyea Team highlights the clinical data on the use of JAN123 to treat CRPS.

Published Case Report

Published in the journal Pain Medicine Case Reports, this article written by the Alyea Team is a case report of the use of JAN123 to treat CRPS.

Orphan Drug Designation

Alyea Therapeautics was granted an Orphan Drug Designation by the FDA to treat CRPS with JAN123.

We’re creating a future where CRPS patients can look forward to pain-free days and nights.

microscope
Who we are?

Alyea Therapeautics

We’re a pharmaceutical company that is developing new medications to treat rare, orphan diseases. We have developed a new oral pill that we believe has several advantages to help suffering patients.

goal
Our Goal

To get a high quality and effective formulation of JAN123 on the market.

Our Founder

Dr. Amol Soin

A quadruple board certified pain management physician who saw the suffering of patients with CRPS and decided to do something about it.

Dr. Soin has invented multiple medications and medical devices to treat pain without addiction.

founder_img
Our Founder’s Journey
  • Multiple Biotech Companies Founder
  • Several Patents Holder
  • Pain Management Research Laboratory Owner
  • Served as president of Ohio Medical Board, American Society of Interventional Pain Physicians, and Society of Interventional Pain Management Surgery Centers.
  • Professor at 3 medical schools
  • Extensive research published in multiple medical journals
  • 5 College Degrees Holder, including two from Ivy League schools (Dartmouth and Brown)

Stay Informed. Stay Hopeful. Together, We Can Overcome CRPS.

Contact us today to get the latest updates on our progress, exclusive insights into new treatments, and a front-row seat to the future of pain relief.